Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/2007
10/25/2007WO2007119623A1 Novel use of g-protein-conjugated receptor and ligand thereof
10/25/2007WO2007119588A1 Brain function-improving agent, and functional food containing the improving agent
10/25/2007WO2007119578A1 Agent for improving nervous system cell functions
10/25/2007WO2007119503A1 Wake-up remedy
10/25/2007WO2007119463A1 2-(cyclic amino)-pyrimidone derivatives as tpk1 inhibitors
10/25/2007WO2007119378A1 Composition containing riboflavin and sesamins
10/25/2007WO2007119367A1 Composition containing biopterin and method for using the same
10/25/2007WO2007119108A2 Inositol derivatives and their uses in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
10/25/2007WO2007118984A1 Use of (s)-roscovitine for manufacturing a medicine
10/25/2007WO2007118903A1 Trisubstituted 1,2,4-triazoles
10/25/2007WO2007118900A1 Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor
10/25/2007WO2007118899A1 Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor
10/25/2007WO2007118859A1 Aryloxyethylamine compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
10/25/2007WO2007118853A1 Benzenesulfonamide compounds and their use as blockers of calcium channels
10/25/2007WO2007118819A2 Novel crystalline compounds
10/25/2007WO2007118363A1 A chinese medicine composition and preparation method and use thereof
10/25/2007WO2007118325A1 Enhancement of memory and/or cognition using substituted butyrophenone compounds
10/25/2007WO2007118318A1 USE OF IMIDAZO[2,1-b)]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN
10/25/2007WO2007091250A8 Enzyme replacement therapy for treating lysosomal storage diseases
10/25/2007WO2007088450A3 Chromane antagonist of the h-3 receptor
10/25/2007WO2007076070A3 Modulators of muscarinic receptors
10/25/2007WO2007070393A3 Mglur1 anatgonists as therapeutic agents
10/25/2007WO2007052169A3 Hypophosphorous acid derivatives and their therapeutical applications
10/25/2007WO2006105998A3 Treatment of cognitive and learning impairment
10/25/2007WO2006103342A9 Indanyl-piperazine derivatives, method for preparing same and pharmaceutical compositions containing same
10/25/2007WO2003011210A3 Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase
10/25/2007US20070249813 recombinant human antibodies containing CDR3 domain having an amino acid sequence with alanine substitutions that specifically bind to human tumor necrosis factor alpha (hTNF alpha ) to treat autoimmune disorders ( rheumatic arthritis, allergy, multiple sclerosis, autoimmune diabetes)
10/25/2007US20070249732 Use of certain phenyl napthyl compounds for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis (ms)
10/25/2007US20070249720 Thiourea Derivative-Containing Pharmaceutical Composition Having Improved Solubility and Bioavailability
10/25/2007US20070249719 Compounds for the treatment of metabolic disorders
10/25/2007US20070249718 Stable gabapentin compositions
10/25/2007US20070249715 treating schizophrenia in a patient by administering an effective amount of 4,4-dimethylcyclohexylamine
10/25/2007US20070249711 Triterpene Compounds which are Effective on Improvement of Brain Function
10/25/2007US20070249703 (Hydroxyphenyl)-1H-Indole-3-Carbaldehyde Oxime Derivatives As Estrogenic Agents
10/25/2007US20070249696 Compounds for the treatment of metabolic disorders
10/25/2007US20070249682 Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications
10/25/2007US20070249679 inhibitor of serotonin reuptake transporter protein; as tachykinin antagonists treating nervous system disorders, psychological disorders, rheumatoid arthritis; 1-[(3,5-dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,3-dihydro-2H-imidazol-2-one; cyclization preparation
10/25/2007US20070249676 Cyanoguanidine prodrugs
10/25/2007US20070249663 Corticotropin-Releasing Factor (CRF) receptor antagonist as therapeutic agent for depression, depressive symptom, or irritable bowel syndrome
10/25/2007US20070249659 melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide
10/25/2007US20070249657 1-Aza-Bicyclo3.3.1Nonanes
10/25/2007US20070249638 Derivatives of triazoly-imidazopyridine and of the triazolypurines useful as ligands of the adenosine A2a receptor and their use as medicaments
10/25/2007US20070249630 Phenethanolamine derivatives for treatment of respiratory diseases
10/25/2007US20070249621 Pharmacological treatment of parkinson's disease
10/25/2007US20070249619 Diarylmethyl Piperazine Derivatives, Preparations Thereof and Uses Thereof
10/25/2007US20070249617 3-(6-p-Tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane; treatment of psychotic disorders such as schizophrenia, mania, depression and anxiety; neurodegenerataive disorders such as senile dementia, Alzhelmer's disease and other intellectual impairment disorders
10/25/2007US20070249612 Substituted 2H-[1,2,4]Triazolo[4,3-A]Pyrazines as Gsk-3 Inhibitors
10/25/2007US20070249606 2,4-dichloro-N-{[1- (isopropylsulfonyl)-4- (morpholine-4- ylcarbonyl)piperidin-4- yl]methyl}benzamide; selective GlyT1 uptake inhibitors; nervous system, psychological disorders; cognition activators; dementia; schizophrenia; Parkinson's/Alzheimer diseases;bipolar disorders; neuroleptic agents
10/25/2007US20070249604 3-Monosubstituted tropane derivatives as nociceptin receptor ligands
10/25/2007US20070249594 Benzothiazine and benzothiadiazine compounds
10/25/2007US20070249588 Nicotinic Acetylcholine Receptor Ligands
10/25/2007US20070249582 Method of Treating Substance Abuse with Quetiapine
10/25/2007US20070249554 Methods for therapy of neurodegenerative disease of the brain
10/25/2007US20070249539 Vascular endothelial growth factor; hypoxia responsive element; amyotrophic lateral sclerosis
10/25/2007US20070249534 Novel medicament for treating neurodegenerative diseases
10/25/2007US20070249004 Truncated glycogen synthase kinase 3 crystallizable polypeptide; drug screening for Alzheimer's Disease treatments, antidiabetic and antiinflammatory agents; exposing a GSK3- beta molecule to a putative inhibitor, and measuring the specific enzymatic activity of said GSK3- beta molecule
10/25/2007US20070248996 Modulators of beta-amyloid peptide aggregation comprising D-amino acids
10/25/2007US20070248702 Use of CB2 receptors agonists for the treatment of Huntington's disease
10/25/2007US20070248606 Treatment of Alzheimer's disease
10/25/2007US20070248586 Oxylipins from stearidonic acid and gamma-linolenic acid and methods of making and using the same
10/25/2007US20070248572 Method for treating diseases with omega interferon
10/25/2007US20070248569 Eye-Drop Vaccine Containing Copolymer 1 for Therapeutic Immunization
10/25/2007DE102004002884B4 Aspernigrin B und Aspernigrin-B-Derivate, sie enthaltende pharmazeutische Zusammensetzungen und deren Verwendung Aspernigrin B-B and Aspernigrin derivatives, pharmaceutical compositions containing them and their use
10/25/2007CA2652826A1 A composition comprising extracts of radix ginseng, folium ginkgo, stigma croci and glycine max and use thereof for treating ischemic cerebrovascular disease
10/25/2007CA2649735A1 Activating agent for peroxisome proliferator activated receptor .delta.
10/25/2007CA2649360A1 Mono and di-substituted oxycodone compounds and compositions
10/25/2007CA2649315A1 Brain function-improving agent, and functional food containing the improving agent
10/25/2007CA2649302A1 Anilino-pyrimidine phenyl and benzothiophene analogs
10/25/2007CA2649287A1 Benzimidazole 5-sulfonamide derivatives as cannabinoid 1 (cb1) receptor ligands
10/25/2007CA2649250A1 Dopaminergic neuron progenitor cell marker 187a5
10/25/2007CA2649150A1 Thioxanthine derivatives and their use as inhibitors of mpo
10/25/2007CA2649076A1 Crystal forms of o-desmethylvenlafaxine
10/25/2007CA2649073A1 Compositions and methods for suppression of amyloid plaque formation associated with neurodegenerative disorders
10/25/2007CA2648892A1 Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor
10/25/2007CA2648891A1 Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor
10/25/2007CA2648548A1 Survival and development of neural cells
10/25/2007CA2648543A1 Aryloxyethylamine compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
10/25/2007CA2648140A1 New crystalline compounds
10/25/2007CA2647694A1 Use of (s)-roscovitine for manufacturing a medicine
10/25/2007CA2647141A1 Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands
10/25/2007CA2645961A1 Aminomethyl pyridine derivatives, method for preparing same and therapeutic use thereof
10/25/2007CA2645833A1 Compositions containing riboflavin and sesamin-class compounds
10/25/2007CA2644979A1 2-(cyclic amino)-pyrimidone derivatives as tpk1 inhibitors
10/25/2007CA2634009A1 Improved synthesis and preparations of duloxetine salts
10/25/2007CA2626005A1 Inositol derivatives and their uses in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
10/24/2007EP1847542A1 Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
10/24/2007EP1847541A1 Fused pyrimidine derivative and uses thereof
10/24/2007EP1847530A1 Diamine derivative
10/24/2007EP1847524A1 Terphenyl derivatives for treatment of Alzheimer's disease
10/24/2007EP1846415A1 Heterocyclic tetracyclic tetrahydrofuran derivatives as 5ht2 inhibitors in the treatment of cns disorders
10/24/2007EP1846414A1 Tetracyclic monoamine reuptake inhibitors for treatment of cns diseases and disorders
10/24/2007EP1846410A2 Dihydroquinazolinones as 5ht modulators
10/24/2007EP1846402A1 3-amino-pyrazolo[3,4b]pyridines used as inhibitors of protein tyrosine kinases for treating angiogenic, hyperproliferative or neurodegenerative diseases
10/24/2007EP1846400A2 Tricyclic delta-opioid modulators
10/24/2007EP1846391A2 Raf inhibitor compounds and methods
10/24/2007EP1846389A1 Imidazole derivatives
10/24/2007EP1846384A1 Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine
10/24/2007EP1846375A1 2-amino-1-phenylethylcarboxamide derivatives
10/24/2007EP1846374A1 Cinnamate salts of a beta-2 adrenergic agonist
10/24/2007EP1846366A1 Norvaline derivative and method for preparation thereof
1 ... 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 ... 1833